How Immune Cells ‘See’ and Respond to Mutations in Cancer Cells
In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.
In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.
Cristina Puig Saus, PhD, who led the work, and co-authors Antoni Ribas, PhD, and Jim Heath, PhD, sat down to discuss the work and its future implications. You can watch that video here, or by playing the video at the top of this page.
For more information about the Nature paper, you can read the UCLA Health story here.
